大学院生研究業績サイト

サカイ　リュウタロウ SAKAI Ryuutaro
酒井　隆太郎

所属立命館大学大学院生命科学研究科生命科学専攻

職種正規生

学会発表
2026/09/08	Health Economic Evaluation of Pancreatic Cancer Risk Control Using Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) in BRCA1/2 Pathogenic Variant Carriers (International Society for Pharmacoeconomics and Outcomes Research（ISPOR）)
2026/09/07	Cost-Effectiveness Analysis of Atezolizumab plus Bevacizumab Combination Therapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma (International Society for Pharmacoeconomics and Outcomes Research（ISPOR）)
2026/09/07	Health Economic Evaluation Model for Breast Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) in BRCA1/2 Pathogenic Variant Carriers (International Society for Pharmacoeconomics and Outcomes Research（ISPOR）)
2025/12/22	BRCA1/2病的バリアント保持者に対する着床前遺伝学的検査を用いた膵癌リスク制御に関する医療経済評価モデルの構築 (国際医薬経済・アウトカム研究学会（ISPOR）日本部会)
2025/11/09	Health Economic Evaluation Model for Breast Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) (International Society for Pharmacoeconomics and Outcomes Research（ISPOR）)
2025/11/09	Health Economic Evaluation Model for Ovarian Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) (International Society for Pharmacoeconomics and Outcomes Research（ISPOR）)
2025/11/09	Health Economic Evaluation Model for Pancreatic Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) (International Society for Pharmacoeconomics and Outcomes Research（ISPOR）)
2025/11/09	Health Economic Evaluation Model for Prostate Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) (International Society for Pharmacoeconomics and Outcomes Research（ISPOR）)
2024/05/08	Cost-Effectiveness Analysis of Tremelimumab As First-Line Therapy for Metastatic Non-Small Cell Lung Cancer in Japan (International Society for Pharmacoeconomics and Outcomes Research（ISPOR）)